Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hippotragus niger

ABSTRACT: Whole-genome re-sequencing of five sable antelope

PROVIDER: PRJNA403774 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8366680_1.fastq.gz	Fastqsanger.gz
	SRR8366680_2.fastq.gz	Fastqsanger.gz
	SRR8366681_1.fastq.gz	Fastqsanger.gz
	SRR8366681_2.fastq.gz	Fastqsanger.gz
	SRR8366677_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 10

Similar Datasets

Hippotragus leucophaeus

Project description:Blue antelope nuclear genomes

| PRJNA776140 | ENA

Diet of Sable Antelope in Texas analyzed via microhistology and Illumina metabarcoding

Project description:Diet of Sable Antelope

| PRJEB23870 | ENA

Hippotragus niger

Project description:Hippotragus niger Genome sequencing and assembly

| PRJNA403773 | ENA

Hippotragus leucophaeus

Project description:Identification of blue antelope museum specimens using mtDNA

| PRJNA776136 | ENA

Hippotragus leucophaeus isolate:NRM590107

Project description:High coverage blue antelope nuclear genome analyses

| PRJNA950236 | ENA

Sable antelope coronavirus US/OH1/2003

Project description:Sable antelope coronavirus US/OH1/2003

| PRJNA18591 | ENA

Project description:metagenome data of sable antelope feces

| PRJNA738686 | ENA

Hippotragus niger variani

Project description:Hippotragus niger variani Genome sequencing

| PRJNA251634 | ENA

Metastatic Uterine Adenocarcinoma in a Sable Antelope (<i>Hippotragus niger</i>).

Project description:A nine-year-old intact female sable antelope (Hippotragus niger) with a six-week history of gradual loss of body condition was found dead by the owner and presented for autopsy. Macroscopic examination revealed an enlarged spleen and liver with the hepatic and splenic parenchyma showing extensive infiltration with firm, white to cream-coloured nodules. The uterus showed a few small, firm, well-demarcated, white-to-cream-coloured nodules in the uterine body. Similar nodules were present in the mediastinum, parietal pleura, heart, and marrow cavity of the femur. Histological analysis of the uterus revealed densely cellular neoplastic proliferations, forming nests, tubules, and acini within an abundant fibrovascular stroma. The samples from the other tissues revealed neoplastic cells with a similar appearance to those seen in the uterus, also forming nests and acini in a fibrovascular stroma. Importantly, multiple neoplastic cells were also seen in the peribronchiolar lymphatic vessels. The neoplastic cells in the uterine sections showed positive immunohistochemical labelling for cytokeratin, as did the neoplastic cells in the sections of liver and parietal pleura, confirming they were of epithelial origin. In addition, transmission electron microscopy of the uterus and liver showed neoplastic cells arranged in groups surrounded by basement membranes and interspersed with collagen fibres. Junctions were present between the cells, and junctional complexes could be seen at some cell surfaces. This confirmed that the neoplastic cells seen in the liver sample were the same as those seen in the uterine sample and were of epithelial origin. Thus, a diagnosis was made of uterine adenocarcinoma with widespread metastasis. This is the first report of uterine adenocarcinoma in a sable antelope.

| S-EPMC9316055 | biostudies-literature

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data